Compare Cytokinetics Inc (CYTK) vs VanEck Gold Miners ETF (GDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs VanEck Gold Miners ETF — how do they compare? Cytokinetics Inc trades at $62.79 (market cap $8.62B), while VanEck Gold Miners ETF trades at $89.46 (market cap $25.65B). The key difference: VanEck Gold Miners ETF is far larger — about 3× Cytokinetics Inc's market cap, and VanEck Gold Miners ETF is trading nearer its 52-week high, Cytokinetics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and VanEck Gold Miners ETF for 76 Days on average.
| CYTK | GDX | |
|---|---|---|
Market Cap | $8.62B | $25.65B |
Volume | 2,594,626 | 16,534,046 |
Sector | Health | — |
52-Week High | $87.26 | $115.84 |
52-Week Low | $54.76 | $68.28 |
Typical Hold Time | 19 Days | 76 Days |
Enterprise Value | $8.72B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.66, up 2.52% on the day, amid a bearish technical signal from moving averages but with oversold RSI readings. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%, reflecting high R&D and commercialization costs. Recent news highlights clinical progress, including positive Phase 3 results for aficamten in non-obstructive HCM and upcoming presentations at the HFSA Annual Scientific Meeting 2026.
The investment case hinges on successful drug commercialization and pipeline execution, with a consensus analyst price target of $112.60 implying significant upside. However, persistent losses, high cash burn, and competitive pressures in the cardiovascular drug market present substantial risks. Near-term catalysts include the Q3 2026 earnings report and regulatory submissions for aficamten.
GDX trades at $89.24, up 4.42% today but facing bearish technical signals with 15 sell indicators versus 4 buy signals. The ETF remains 22% below its peak despite gold trading near $4,270, creating a potential catch-up opportunity. Recent institutional activity shows mixed sentiment with Allworth Financial and HB Wealth Management reducing positions while Ameritas Advisory Services increased its stake by 315.7%.
Gold miners offer leverage to gold prices but face volatility from interest rate sensitivity and operational risks. Current technical weakness suggests near-term pressure, though long-term fundamentals remain supported by gold's defensive characteristics amid macroeconomic uncertainty. The divergence between physical gold performance and miner valuations presents both risk and opportunity for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About VanEck Gold Miners ETF
The fund normally invests at least 80% of its total assets in common stocks and depositary receipts of companies involved in the gold mining industry. The index is a modified market-capitalization weighted index primarily comprised of publicly traded companies involved in the mining for gold and silver. The fund is non-diversified.
Read more on GDX →
